Ashley Gallagher, MA

Emily Leppien, PharmD, BCPS, BCPP, clinical associate professor of pharmacy practice at Binghamton University, discusses identifying potential red flags for substance use disorder.

National Adverse Drug Event Awareness Day occurs annually on March 24 to raise awareness about minimizing the risk of adverse events caused by medications.

Jeffrey Gudin, MD, faculty in the department of anesthesiology and pain management at the University of Miami, said topical analgesics are safer alternatives to systemic medications.

Darcy Aslett, PharmD, residency program director for PGY-1 community-based residency at St. Luke's Health System, discusses clinical services in pharmacies for underserved patients.

Ravi Patel, PharmD, MBA, MS, lead innovation advisor in the School of Pharmacy at the University of Pittsburgh, discusses challenges with new technology and the future of artificial intelligence in pharmacy.

Elizabeth Pogge, PharmD, professor in the College of Pharmacy at Midwestern University, discusses the safety and efficacy of anticoagulation for this population.

Ravi Patel, PharmD, MBA, MS, lead innovation advisor in the School of Pharmacy at the University of Pittsburgh, explains how artificial intelligence can be used in pharmacy.

Elizabeth Pogge, PharmD, professor in the College of Pharmacy at Midwestern University, discusses initiating anticoagulation for older adults as well as the risk-benefit balance of the therapy.

Sally Arif, PharmD, professor in the College of Pharmacy at Midwestern University, discusses how pharmacists can effectively communicate with diverse patients.

Jade Ranger, PharmD, co-owner and pharmacist at the Prescription Shoppe, discussed administering vaccines during the COVID-19 pandemic.

Pharmacists play a critical role in public education, and the potential for expanding clinical services is evident.

Jade Ranger, PharmD, discusses her experiences during the COVID-19 pandemic as one of the first pharmacies to receive the COVID-19 vaccines.

Jeffery Goad, PharmD, MPH, president of the National Foundation for Infectious Diseases, reflects on the COVID-19 pandemic 5 years later.

The new approval is an oral suspension for patients with hypertension and left ventricular hypertrophy and for the treatment of diabetic nephropathy.

Pharmacists are resilient, community-focused professionals who played a pivotal role in navigating the unprecedented challenges of the COVID-19 pandemic.

Because of their accessibility in the community, pharmacists can help to deliver balanced and individualized services and address social determinants of health.

The most commonly reported symptoms of long COVID include neurological, muscular, respiratory, and psychological.

Tirzepatide and semaglutide show long-term health care cost savings but, the high cost of the medications offset the savings.

Among the drugs presented, Biktarvy and lenacapavir, teropavimab, and zinlirvimab (LTZ) demonstrate rates of suppression of HIV, and vesatolimod is well tolerated.

These findings challenge the common assumption that older adults might struggle to use more advance medical devices.

This year’s meeting will take place from March 21 to 24 in Nashville, Tennessee.

Additional data shows that an investigational drug, given every 4 months with Apretude, kept viral levels suppressed for patients who were already on stable treatment.

These findings are shared as late-breaking data at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI) being held in San Francisco, California.

Approximately, 62% of respondents stated that the number of active drug shortages could potentially increase by more than 25% within the next 5 years.

Deucravacitinib (Sotyktu) also demonstrates improvements in signs and symptoms, extra-articular manifestations, and patient-reported outcomes.

Patients aged 12 to under 18 saw clinically meaningful regrowth on the scalp, eyebrow, and eyelashes with both high-dose and low-dose treatment.

Approximately 89.7% of patients taking CagriSema achieve the coprimary end point of weight loss of 5% or more compared with 30.3% on the placebo.

Investigators note that low itch and mild disease severity are maintained following a treatment-free interval of 80 days.

Non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol levels could potentially be a valuable biomarker for determining the risk of diabetic kidney disease.

In a previous study, results showed that patients taking semaglutide could be at a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION), causing blindness.